ALISON trial data presented at ASCO 2025 demonstrates successful induction of tumor-directed immune responses in high-risk ovarian cancer

What we doOur approachPipelineTechnologyPublicationsPatient and Clinical Perspectives
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
ALISON trial data presented at ASCO 2025 demonstrates successful induction of tumor-directed immune responses in high-risk ovarian cancer
 8:00:00 AM

Keep reading
Data presented at EHA strengthens Mendus’ programs in myeloid leukemiasRead